KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $1.4 billion.

  • Jazz Pharmaceuticals' Free Cash Flow rose 22.34% to $474.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.5 million, marking a year-over-year decrease of 53.93%. This contributed to the annual value of $1.4 billion for FY2024, which is 27.13% up from last year.
  • According to the latest figures from FY2024, Jazz Pharmaceuticals' Free Cash Flow is $1.4 billion, which was up 27.13% from $1.1 billion recorded in FY2023.
  • Jazz Pharmaceuticals' Free Cash Flow's 5-year high stood at $1.4 billion during FY2024, with a 5-year trough of $750.9 million in FY2021.
  • Over the past 3 years, Jazz Pharmaceuticals' median Free Cash Flow value was $1.2 billion (recorded in 2022), while the average stood at $1.2 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Free Cash Flow decreased by 15.12% in 2021, and later soared by 65.53% in 2022.
  • Jazz Pharmaceuticals' Free Cash Flow (Yearly) stood at $884.6 million in 2020, then fell by 15.12% to $750.9 million in 2021, then skyrocketed by 65.53% to $1.2 billion in 2022, then fell by 14.07% to $1.1 billion in 2023, then rose by 27.13% to $1.4 billion in 2024.